期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Bruton酪氨酸激酶抑制剂在套细胞淋巴瘤中的研究进展 被引量：2

Research progress of Bruton tyrosine kinase inhibitors in mantle cell lymphoma
原文传递
导出
摘要 套细胞淋巴瘤（MCL）是一种高度异质性的疾病，其临床表现多种多样，对常规化疗药物多不敏感，预后相对较差。以依鲁替尼（ibrutinib）为代表的新型Bruton酪氨酸激酶（BTK）靶向药物的出现为MCL的治疗提供了新希望。文章就BTK抑制剂在MCL治疗中的最新研究进展进行综述。 Mantle cell lymphoma （MCL）, is a disease .with high heterogeneity, which is insensitivity to the chemotherapy and presents poor prognosis. Appearance of the Bruton tyrosine kinase （BTK） targeted inhibitors, such as ibrutinib, provides novel treatment strategy for MCL. This review focused on the latest achievements of BTK inhibitors in MCL treatment.
作者 周香香 王欣
机构地区 山东大学附属省立医院血液科
出处 《白血病．淋巴瘤》 CAS 2016年第6期377-380,共4页 Journal of Leukemia & Lymphoma
基金 国家自然科学基金（81473486、81270598）
关键词 淋巴瘤 套细胞 Bruton酪氨酸激酶抑制剂 依鲁替尼 Lymphoma, mantle-cell Bruton tyrosine kinase inhibitor Ibrutinib
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献24

  • 1Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma [ J ]. J Clin Oncol, 2016, 34 ( 11 ) : 1256-1269. DOI: 10.1200/JCO.2015. 63.5904.
  • 2Gayko U, Fung M, Clow F, et al. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies [ J ]. Ann N Y Acad Sci, 2015, 1358 : 82-94. DOI: 10.1111/nyas.12878.
  • 3Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 [ J ]. Blood, 2011, 117 ( 23 ) : 6287-6296. DOI: 10.1182/blood-2011-01- 328484.
  • 4Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma [ J ]. N Engl J Mod, 2013, 369 ( 6 ) : 507-516. DOI: lO.1056/NEJMoa1306220.
  • 5Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study [ J ]. Lancet, 2016, 387 ( 10020 ) : 770-778. DOI: 10.1016/S0140- 6736 ( 15 ) 00667-4.
  • 6Khouri IF, Jabbour E, Saliba RM, et al. Ibrutinib in patients ( Pts ) with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia ( CLL ) with relapsed disease post allogeneic stem cell transplantation ( alloSCT ) [ J ]. Blood, 2015, 126 ( 23 ) : 4345.
  • 7Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma:a single- centre, open-label, phase 2 trial [ J ]. Lancet Oncol, 2016, 17 ( 1 ) : 48-56. DOI: 10.1016/S1470-2045 ( 15 )00438-6.
  • 8Kolibaba K, Burke JM, Brooks HD, et al. Ublituximab ( TG- 1101 ), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with Ibrutinib is highly active in patients with relapsed and/or refractory mantle cell lymphoma; results of a phase II trial [ J ]. Blood, 2015, 126 ( 23 ) : 3980.
  • 9Ruella M, Kenderian SS, Shestova O, et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T ceils ( CART19 ) improves responses against mantle cell lymphoma [ J ]. Clin Cancer Res, 2016, 22 ( 11 ) : 2684-2696. DOI: 10.1158/1078- 0432.CCR-15-1527.
  • 10Galanina N, Petrich A, Nabhan C. The evolving role of lenalidomide in non-Hodgkin lymphoma [ J ]. Leuk Lymphoma, 2016, 57 ( 7 ) : 1507-1516. DOI: 10.3109/10428194.2016.1146949.

同被引文献6

引证文献2

白血病．淋巴瘤
2016年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部